Incidence of TNS After Intrathecal Lidocaine v.s Bupivacaine

Orthopedic Disorder Clinical Trial

Official title:

Is Lidocaine Really Guilty? A Prospective, Randomized, Double Blind Comparison of the Incidence of TNS After Intrathecal Lidocaine Administration vs. Intrathecal Bupivacaine in Patients Undergoing Spinal Anesthesia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03862287
• Other study ID #: 2019-4823
• Status: Recruiting
• Phase: N/A
• Start date: November 1, 2018
• Est. completion date: December 2019

Study information

• Verified date: March 2019
• Source: McGill University Health Center
• Contact: Juan F Asenjo
• Phone: 5149341934
• Email: jfasenjog[@]yahoo.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will look into the incidence of Transient neurological symptoms (TNS) after the intrathecal use of lidocaine in comparison to intrathecal Bupivacaine.

Description:

Ever since the introduction of Spinal anesthesia in 1898 by the German surgeon August Bier, the approach gained wide acceptance by the anesthesia community 1. Since that time, the technique has evolved to accommodate a wide variety of surgical procedures, making it one of the most common regional anesthesia modalities used. The advancement of the anesthesia field has led to the advancement of the technique it self, specially the drugs used in it.

A wide range of local anesthetics has been introduced after the initial successful intrathecal use of cocaine. Starting with amylocaine, and later with the introduction of various local anesthetics such as procaine, 2-chloroprocaine, lidocaine, tetracaine, mepivacaine, prilocaine, bupivacaine, with ropivacaine and levobupivacaine being introduced last. Many of these drugs have fallen out of favour due to various reasons, with Lidocaine, procaine, mepivacaine, ropivacaine and bupivacaine still being used in clinical practice 2.

The choice of the local anesthetic used depends on many factors such as the duration of the operation, the type of surgery and the degree of motor blockade desired. With the advancement of surgery and the increase in day surgical cases, a need for a fast acting, short in duration local anesthetic that allows fast recovery and early discharge has emerged. Of all the local anesthetic drugs available, Lidocaine is one of the drugs that fulfills these needs.

Common complications associated with the use of this technique include headache (5%), backache (11%), hypotension, bradycardia, nausea and vomiting (20%), urinary retention, hypothermia and transient neurological syndrome (TNS). More serious complications include total spinal, infection (meningitis/ encephalitis) and epidural hematoma (<1 in 150,000). On the other hand, complications related to receiving General Anesthesia for the same procedure are similar, with higher chances of nausea and vomiting or airway problems.

TNS is defined as back pain and/or dysesthesia radiating bilaterally to the legs or buttocks after total recovery from spinal anesthesia, manifesting within 24 hours after the surgery and typically lasting less than a week. The etiology of TNS is unknown. Possible contributing factors to the development of TNS include sciatic nerve stretching causing neural ischemia, vasoconstriction of spinal cord arteries, patient positioning, direct needle injury and pooling of local anesthetic in the sacral region. The pathophysiology of TNS is unknown, and there is no specific lab test to diagnose this complication. Treatment of TNS, includes bed rest, administration of nonsteroidal anti inflammatory drugs and sometimes the addition of an opioid is needed 3.

All local anesthetics have been shown to cause TNS, with lidocaine appearing to have the greatest risk. The first reported case of TNS after the single shot administration of 5% hyperbaric lidocaine was published by Schneider and colleagues in 1993 4, which was confirmed later by several other studies 5-9. The reported incidence of TNS after the administration of lidocaine ranges from 10%-40% 10-13. In a more resent study done by F. Salazar et al. the incidence of TNS with lidocaine was reported to be 2.5%, much lower than what was previously described in the literature 14.

Furthermore, in an internal audit done at the MGH looking at all spinal anesthesia cases performed by Dr. Asenjo in the past two years, TNS incidence was found to be 2.7%, far less than what the literature describes, and correlates more with what F. Salazar et al. found in their study. We want to clarify this discrepancy in the incidence of TNS with lidocaine since this is a very inexpensive agent, with a short to intermediate duration of action and readily available world wide. With this purpose we have designed a randomized controlled trial to test the hypothesis that the incidence of TNS after spinal anesthesia with lidocaine is much lower than what was previously described in the literature. This trial will also look at the natural course of the symptoms of TNS.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 160
• Est. completion date: December 2019
• Est. primary completion date: December 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• ASA I-III male and female patients aged between 18 to 80 years old, who will receive spinal anesthesia for surgeries lasting less than one hour.

Exclusion Criteria:

• Patients younger than 18 years old.

• ASA physical status >3.

• Immunosuppression or high risk of infection.

• Contraindications to receiving spinal anesthesia (e.g. coagulation impairment).

• Patients with psychosis

• Patients with preexisting back pain.

• Patients with cognitive impairment

• Allergies to local anesthetics, analgesics or any medication used in the study.

• Patients with chronic regular opioid usage

• Presence of preexisting neurological symptoms.

Related Conditions & MeSH terms

• Leg Injuries
• Musculoskeletal Diseases
• Orthopedic Disorder

Intervention

Drug:
• Lidocaine
See arm description.
• Bupivacaine Hcl 0.5% Inj_#2
See arm description.

Locations

Country	Name	City	State
Canada	Montreal General Hospital	Montreal	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
McGill University Health Center

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Transient Neurological Symptoms	To determine the incidence of TNS following the use of intrathecal Lidocaine as compared with Bupivacaine	Day 1
Primary	Transient Neurological Symptoms	To determine the incidence of TNS following the use of intrathecal Lidocaine as compared with Bupivacaine	Day 3
Secondary	Transient Neurological Symptoms	To determine the incidence of TNS following the use of intrathecal Bupivacaine	Day 1 and day 3 postoperative
Secondary	Transient Neurological Symptoms	To determine the incidence of TNS following the use of either intrathecal Lidocaine and Bupivacaine in patients operated in the lithotomy position	Day 1 and day 3 postoperative